Treatment options in imatinib-resistant chronic myelogenous leukemia

The Annals of Pharmacotherapy
Helen M Marshall, Julia M Hammond

Abstract

To discuss new therapeutic options available in the treatment of chronic myelogenous leukemia (CML) in patients who failed or were intolerant to imatinib therapy. Literature was accessed via MEDLINE (1966-May 2007), EMBASE (1991-3rd quarter 2007), the Proceedings of the American Society of Hematology (2000-2006), and the Proceedings of the American Society of Clinical Oncology (2000-2007). Search terms included imatinib, dasatinib, nilotinib, and chronic myelogenous leukemia. Meeting abstracts and studies that reported preclinical and Phase 1, 2, and 3 trials published in English are included. Imatinib is the standard of care for CML; however, some patients develop resistance or are intolerant to the drug. Phase 1 and 2 clinical data for the more potent tyrosine kinase inhibitors, dasatinib and nilotinib, are promising. Hematologic and cytogenetic responses are reported with both. There does not appear to be cross-resistance between the drugs, although neither is effective against all mutations of the hallmark molecular marker, the Philadelphia chromosome. Novel agents are also being examined for the treatment of patients with CML, including aurora kinase and farnesyl transferase inhibitors, as well as combination therapies. Da...Continue Reading

References

Oct 19, 2000·Journal of the National Cancer Institute·C Gambacorti-PasseriniM D'Incalci
Mar 1, 2002·The New England Journal of Medicine·David G Savage, Karen H Antman
Mar 15, 2003·The New England Journal of Medicine·Stephen G O'BrienUNKNOWN IRIS Investigators
Oct 10, 2003·The New England Journal of Medicine·John M Goldman, Junia V Melo
Dec 17, 2003·Current Opinion in Hematology·Valentina NardiGeorge Q Daley
Jul 9, 2004·International Journal of Hematology·Chikashi Yoshida, Junia V Melo
Sep 13, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jorge Cortes, Hagop Kantarjian
Oct 6, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Thomas O'HareBrian J Druker
Jun 16, 2006·The New England Journal of Medicine·Moshe TalpazCharles L Sawyers
Jun 16, 2006·The New England Journal of Medicine·Hagop KantarjianOliver G Ottmann
Nov 25, 2006·Hematology·Michael J Mauro
Dec 8, 2006·The New England Journal of Medicine·Brian J DrukerUNKNOWN IRIS Investigators

❮ Previous
Next ❯

Citations

Mar 24, 2010·Acta Oncologica·Yolanda B BrauchliStephan Krähenbühl
Oct 30, 2013·Critical Reviews in Toxicology·Bruce HammondUNKNOWN ILSI International Food Biotechnology Committee Task Force on Use of Mammalian Toxicology Studies in Safety Assessment of GM

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.